HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Abstract : Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity. Ongoing trials are investigating the efficacy and safety of bevacizumab in various stages of breast cancer and in breast cancer with a range of hormonal or receptor characteristics.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-00484825
Contributor : Philippe Saas Connect in order to contact the contributor
Submitted on : Wednesday, May 19, 2010 - 11:54:14 AM
Last modification on : Friday, January 14, 2022 - 3:08:20 AM

Links full text

Identifiers

Collections

Citation

Arlene Chan, D. W. Miles, Xavier Pivot. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.. Annals of Oncology, Elsevier, 2010, 21 (12), pp.2305-15. ⟨10.1093/annonc/mdq122⟩. ⟨inserm-00484825⟩

Share

Metrics

Record views

45